P16INK4a overexpression and survival in osteosarcoma patients: A meta analysis

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 9, 2014, Pages 6091-6096

  Bu, Jie ^a   Li, Hui ^a   Liu, Li Hong ^a   Ouyang, Yu Rong ^a   Guo, Hong Bin ^a   Li, Xiao Yang ^a   Xiao, Tao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Meta analysis; Osteosarcoma P16INK4a expression; Survival

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

BONE NEOPLASMS; CHEMISTRY; HUMAN; META ANALYSIS; MORTALITY; ODDS RATIO; OSTEOSARCOMA; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SURVIVAL ANALYSIS; TIME FACTOR; UPREGULATION;

BIOMARKERS, TUMOR; BONE NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; ODDS RATIO; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; UP-REGULATION;

EID: 84911929214     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Miao J, Wu S, Peng Z, Tania M and Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol 2013; 34: 2093-2098.
2. Hameed M and Dorfman H. Primary malignant bone tumors--recent developments. Semin Diagn Pathol 2011; 28: 86-101.
3. Mirabello L, Troisi RJ and Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115: 1531-1543.
4. Zou C, Shen J, Tang Q, Yang Z, Yin J, Li Z, Xie X, Huang G, Lev D and Wang J. Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. Cancer 2012; 118: 1845-1855.
5. Knosel T, Altendorf-Hofmann A, Lindner L, Issels R, Hermeking H, Schuebbe G, Gibis S, Siemens H, Kampmann E and Kirchner T. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier. J Clin Pathol 2014; 67: 592-598.
6. Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A, Arkan MC, Kirchner T and Greten FR. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010; 18: 135-146.
7. Honoki K, Stojanovski E, McEvoy M, Fujii H, Tsujiuchi T, Kido A, Takakura Y and Attia J. Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis. Cancer 2007; 110: 1351-1360.
8. Zong L, Chen P, Jiang J, Wang H and Wang L. Correlation between p16 expression and malignant risk of gastrointestinal stromal tumor: evidence from nine studies. Hepatogastroenterology 2012; 59: 1458-1463.
9. Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J and Lin X. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. PLoS One 2013; 8: e54970.
10. Jiang W, Wang PG, Zhan Y and Zhang D. Prognostic value of p16 promoter hypermethylation in colorectal cancer: a meta-analysis. Cancer Invest 2014; 32: 43-52.
11. Meng L, Yu X, Du D and Wang G. The expression and significance of the P16 gene in osteosarcoma [article in Chinese]. Shandong Med J 1999; 19-20.
12. Li L, Wang Y, Liu Y and Li Z. Clinical signification of express of tumor supressor genes and proliferative in osteosarcoma [article in Chinese]. J Clin Orthop 1999; 164-166.
13. Xiao Z, Cai Y and Lin Q. Preliminary research on the expression of rumor suppressor gene p16 protein in human osteosarcoma [article in Chinese]. Zhejiang Clin Med J 2000; 653-654.
14. Maitra A, Roberts H, Weinberg AG and Geradts J. Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. Int J Cancer 2001; 95: 34-38.
15. Li W, Zhao J and Pi G. P16 gene exppression and clinical significance in human osteosarcoma [article in Chinese]. J Chin Pract Diag Ther 2005; 483-484, 487.
16. Oh JH, Kim HS, Kim HH, Kim WH and Lee SH. Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin Orthop Relat Res 2006; 442: 216-222.
17. Lei N, Pan X, Qi Y and Fang Y. Expressions of P16 and proliferating cell nuclear antigen in osteosarcoma and clinical significances [article in Chinese]. J Jilin Univ-Med 2009; 519-521.
18. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton- Jansen AM and Hogendoorn PC. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009; 219: 294-305.
19. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
20. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
21. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
22. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
23. Ta HT, Dass CR, Choong PF and Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 2009; 28: 247-263.
24. Miller BJ, Cram P, Lynch CF and Buckwalter JA. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. J Bone Joint Surg Am 2013; 95: e89.
25. Folio C, Zalacain M, Zandueta C, Ormazabal C, Sierrasesumaga L, San Julian M, de las Rivas J, Toledo G, Lecanda F and Patino-Garcia A. Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival. Cancer Biomark 2011; 10: 35-41.
26. Borys D, Canter RJ, Hoch B, Martinez SR, Tamurian RM, Murphy B, Bishop JW and Horvai A. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy. Hum Pathol 2012; 43: 1948-1954.
27. Wen X, Liu H, Yu K and Liu Y. Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis. Tumour Biol 2014; 35: 845-848.